La Jolla Pharmaceutical (LJPC) to Cut Workforce
La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced that, following the negative results of the Riquent Phase 3 interim efficacy analysis, the Company is taking steps to reduce costs to preserve its remaining cash and other assets, including a substantial reduction in personnel and other operating expenses. In addition to working to maximize the value of the Company's cash and remaining assets, the Company is evaluating strategic options such as winding down the business or the sale of the Company.
"We are very disappointed that the Riquent(R) program was not successful," said Deirdre Y. Gillespie, M.D., President and CEO of La Jolla Pharmaceutical Company. "Following the receipt of the interim efficacy results, we have undertaken activities to rapidly reduce costs, paring down to the minimum necessary to carry out basic operations and address contractual obligations. Unfortunately, Riquent was our sole significant asset. The only other program in our research pipeline targeted SSAO inhibitors which are at an early preclinical stage and of minimum value." [SM]
"We are very disappointed that the Riquent(R) program was not successful," said Deirdre Y. Gillespie, M.D., President and CEO of La Jolla Pharmaceutical Company. "Following the receipt of the interim efficacy results, we have undertaken activities to rapidly reduce costs, paring down to the minimum necessary to carry out basic operations and address contractual obligations. Unfortunately, Riquent was our sole significant asset. The only other program in our research pipeline targeted SSAO inhibitors which are at an early preclinical stage and of minimum value." [SM]
You May Also Be Interested In
- La Jolla Pharmaceutical Announces Results of Annual Stockholders Meeting
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
- BofA (BAC), Barclays (BCS) to Sell Remaining Archstone Interest in $1.58B Deal to Lehman Bros.
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
